Theranexus SA
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France. Show More...
-
Website https://www.theranexus.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.00 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR -0.31 -0.94 -0.68 -1.7 -1.54 -1.54 Dividends EUR Payout Ratio % * Shares Mil 2.0 2.0 3.0 3.0 4.0 4.0 Book Value Per Share * EUR -0.2 5.17 2.79 2.63 Free Cash Flow Per Share * EUR -1.1 -1.39 -2.37 Return on Assets % -19.02 -56.6 -18.19 -27.03 -32.61 -32.61 Financial Leverage (Average) 1.62 32.06 1.12 1.46 1.63 1.63 Return on Equity % -30.93 -179.65 -23.16 -34.15 -50.03 -50.03 Return on Invested Capital % -23.61 -74.9 -19.24 -29.27 -37.23 -37.23 Interest Coverage -66.07 -17.89 -21.11 -123.39 -73.01 -73.01 Current Ratio 31.92 24.62 16.46 8.99 4.77 4.77 Quick Ratio 23.64 17.12 16.46 7.76 3.87 3.87 Debt/Equity 0.3 19.53 0.06 0.31 0.35 0.35